These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17076269)

  • 1. Redirecting splicing to address dystrophin mutations: molecular by-pass surgery.
    Wilton SD; Fletcher S
    Prog Mol Subcell Biol; 2006; 44():161-97. PubMed ID: 17076269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.
    Wilton SD; Fletcher S
    Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Exon Skipping Can Address a Multi-Exon Duplication in the Dystrophin Gene.
    Greer K; Johnsen R; Nevo Y; Fellig Y; Fletcher S; Wilton SD
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotides, exon skipping and the dystrophin gene transcript.
    Wilton SD; Fletcher S
    Acta Myol; 2005 Dec; 24(3):222-9. PubMed ID: 16629057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping.
    Mitrpant C; Fletcher S; Wilton SD
    Curr Mol Pharmacol; 2009 Jan; 2(1):110-21. PubMed ID: 20021451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping.
    Bertoni C; Lau C; Rando TA
    Hum Mol Genet; 2003 May; 12(10):1087-99. PubMed ID: 12719373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple exon skipping strategies to by-pass dystrophin mutations.
    Adkin CF; Meloni PL; Fletcher S; Adams AM; Muntoni F; Wong B; Wilton SD
    Neuromuscul Disord; 2012 Apr; 22(4):297-305. PubMed ID: 22182525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
    Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
    Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.
    Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD
    PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exon skipping and Duchenne muscular dystrophy: hope, hype and how feasible?
    Wilton SD; Fletcher S
    Neurol India; 2008; 56(3):254-62. PubMed ID: 18974551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ; Graham IR; Malerba A; Dickson G
    Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.
    Madden HR; Fletcher S; Davis MR; Wilton SD
    Hum Mutat; 2009 Jan; 30(1):22-8. PubMed ID: 18570328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.